omtx705
mAbexperimentalADC
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2022 (NCT05547321)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Fibroblast activation protein alphaINHIBITOR
FAP inhibitor
Chemistry & pharmacology
- Payload
- unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05547321 | Phase 1 | Oct 31, 2022 | Biotrial, Certara, Clinigen, Inc., Oncomatryx Biopharma S.L., SFBC Anapharm |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biotrial | For profit | 1 | 0 | 1 | 2022 |
| Certara | For profit | 1 | 0 | 1 | 2022 |
| Clinigen, Inc. | For profit | 1 | 0 | 1 | 2022 |
| Oncomatryx Biopharma S.L. | For profit | 1 | 1 | 1 | 2022 |
| SFBC Anapharm | For profit | 1 | 0 | 1 | 2022 |
5 organizations
Page 1 / 1